Synthesis, characterization, antioxidant and anticancer activities of a new Schiff base and its M(II) complexes derived from 5-fluorouracil

Savcı, Ahmet; Buldurun, Kenan; Alkış, Mehmet Eşref; Alan, Yusuf; Turan, Nevin

doi:10.1007/s12032-022-01774-0

Cited by 12 publications

(5 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of cobalt-alkyne complexes, encapsulated propargylates of acetylsalicylic acid (Co-Ass, Figure 9) showed a potent anticancer effect, especially against breast cancer cells. [100,101] Minor differences in lipophilicity between the complex and the free ligand may have a significant impact on their activities. Cobalt alkyne complexes do not appreciably bind DNA in biological systems, and evidence suggests that the efficiency of Co-Ass is mostly dependent on how the ligand acetylsalicylic acid (aspirin) interacts with cyclooxygenase enzymes (COX-1 and COX-2).…”

Section: Cobalt Complexes In Cancer Therapymentioning

confidence: 99%

“…The most common Co compounds that have attracted interest as anticancer agents are hexacarbonyldicobalt clusters with alkyne ligands, [CoIII(NH 3 ) 6 ]Cl 3 , [CoIII(NH 3 ) 6 ]Cl 3 , and Co(II) and/or Co(III) complexes containing cytotoxic thiouracil mithramycin and mustamine ligands, as well as Co(III) complexes with Schiff's base ligands, such as salen. In the case of cobalt‐alkyne complexes, encapsulated propargylates of acetylsalicylic acid (Co‐Ass, Figure 9) showed a potent anticancer effect, especially against breast cancer cells [100,101] …”

Section: Metal Complexes Cancer Chemotherapeuticsmentioning

confidence: 99%

See 1 more Smart Citation

Emerging Trends in Metal‐based Anticancer Agents: Drug Design to Clinical Trials and their Mechanism of Action

Temesgen,

Ananda Murthy,

Enyew

et al. 2023

ChemistrySelect

View full text Add to dashboard Cite

Metal‐based therapeutic strategies have been effectively used to treat a number of diseases since the ancient period. However, the issue that emerged at this time was the indistinct barrier between therapeutic and toxic doses. After the discovery of cisplatin, a breakthrough was made for these challenges, and vital signs of progress were shown in the medicinal potential of metal complexes. Consequently, nowadays many metal‐based drugs, especially in cancer treatments, are under investigation. Nevertheless, due to a greater focus on clinical relevance, a few of these drugs are currently approved, and many more are in clinical trials waiting for approval. Therefore, the design, development, and clinical applications of several metal‐based anti‐cancer agents and their efficacy are highlighted in this review. Moreover, this review is intended to present a comprehensive overview of metal‐based anticancer agents, their targets of drug design and development and their mechanisms of action in cancer treatments.

show abstract

Section: Cobalt Complexes In Cancer Therapymentioning

confidence: 99%

Section: Metal Complexes Cancer Chemotherapeuticsmentioning

confidence: 99%

Emerging Trends in Metal‐based Anticancer Agents: Drug Design to Clinical Trials and their Mechanism of Action

Temesgen,

Ananda Murthy,

Enyew

et al. 2023

ChemistrySelect

View full text Add to dashboard Cite

show abstract

“…Hydrazides have been employed as electron acceptors as well in analytical chemistry [ 12 ]. Various effective compounds, such as iproniazide and isoniazide, are as anti-tubercular medications [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Synthesis, characterization, DFT calculations and biological activity of new Schiff base complexes

Alkhatib,

Alsulami

2023

Heliyon

View full text Add to dashboard Cite

“…[1 -4] Schiff bases and their metal complexes are commonly employed in a variety of applications, including anticancer, anti-HIV (human immunodeficiency virus), antiradical, antibacterial, antifungal, antineoplastic activities, bio-modeling techniques, and DNA cleavage. [5][6][7] Glioblastoma is the most commonly seen primary brain cancer with the highest severity. It has a median survival of about 14-15 months.…”

Section: Introductionmentioning

confidence: 99%

“…Schiff bases are considered promising precursors for the synthesis of new bioactive compounds of medicinal relevance due to their biological and pharmacological importance and ability to form chelates with various transition metals [1–4] . Schiff bases and their metal complexes are commonly employed in a variety of applications, including anticancer, anti‐HIV (human immunodeficiency virus), antiradical, antibacterial, antifungal, antineoplastic activities, bio‐modeling techniques, and DNA cleavage [5–7] …”

Section: Introductionmentioning

confidence: 99%

Electroporation Enhances the Anticancer Effects of Novel Cu(II) and Fe(II) Complexes in Chemotherapy‐Resistant Glioblastoma Cancer Cells

Alkış

Buldurun

Alan

et al. 2023

Chemistry & Biodiversity

Self Cite

View full text Add to dashboard Cite

Schiff base ligand (L) was obtained by condensation reaction between 4-aminopyrimidin-2(1H)-one (cytosine) with 2-hydroxybenzaldehyde. The synthesized Schiff base was used for complexation with Cu(II) and Fe(II) ions used by a molar (2 : 1 mmol ration) in methanol solvent. The structural features of ligand, Cu(II), and Fe(II) metal complexes were determined by standard spectroscopic methods (FT-IR, elemental analysis, proton and carbon NMR spectra, UV/VIS, and mass spectroscopy, magnetic susceptibility, thermal analysis, and powder X-ray diffraction). The synthesized compounds (Schiff base and its metal complexes) were screened in terms of their anti-proliferative activities in U118 and T98G human glioblastoma cell lines alone or in combination with electroporation (EP). Moreover, the human HDF (human dermal fibroblast) cell lines was used to check the biocompatibility of the compounds. Anti-proliferative activities of all compounds were ascertained using an MTT assay. The complexes exhibited a good anti-proliferative effect on U118 and T98G glioblastoma cell lines. In addition, these compounds had a negligible cytotoxic effect on the fibroblast HDF cell lines. The use of compounds in combination with EP significantly decreased the IC 50 values compared to the use of compounds alone (p < 0.05). These results show that newly synthesized Cu(II) and Fe(II) complexes can be developed for use in the treatment of chemotherapy-resistant U118 and T98G glioblastoma cells and that treatment with lower doses can be provided when used in combination with EP.

show abstract

Synthesis, characterization, antioxidant and anticancer activities of a new Schiff base and its M(II) complexes derived from 5-fluorouracil

Cited by 12 publications

References 67 publications

Emerging Trends in Metal‐based Anticancer Agents: Drug Design to Clinical Trials and their Mechanism of Action

Emerging Trends in Metal‐based Anticancer Agents: Drug Design to Clinical Trials and their Mechanism of Action

Synthesis, characterization, DFT calculations and biological activity of new Schiff base complexes

Electroporation Enhances the Anticancer Effects of Novel Cu(II) and Fe(II) Complexes in Chemotherapy‐Resistant Glioblastoma Cancer Cells

Contact Info

Product

Resources

About